These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 12098093)

  • 1. Hemophilia A--from basic science to clinical practice.
    Klinge J; Ananyeva NM; Hauser CA; Saenko EL
    Semin Thromb Hemost; 2002 Jun; 28(3):309-22. PubMed ID: 12098093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular genetics of hemophilia A].
    De Brasi CD; Slavutsky IR; Larripa IB
    Medicina (B Aires); 1996; 56(5 Pt 1):509-17. PubMed ID: 9239887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of hemophilia A: from protein replacement to AAV-mediated gene therapy.
    Youjin S; Jun Y
    Biotechnol Lett; 2009 Mar; 31(3):321-8. PubMed ID: 18979215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.
    Liu L; Mah C; Fletcher BS
    Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the understanding of the molecular biology of hemophilia A: possible implications towards a more effective therapeutic regime.
    Scheiflinger F; Dorner F
    Wien Klin Wochenschr; 1999 Mar; 111(5):172-80. PubMed ID: 10226347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of bleeding disorders: basic science.
    Ofosu FA; Santagostino E; Grancha S; Marco P
    Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives.
    Ananyeva NM; Lacroix-Desmazes S; Hauser CA; Shima M; Ovanesov MV; Khrenov AV; Saenko EL
    Blood Coagul Fibrinolysis; 2004 Mar; 15(2):109-24. PubMed ID: 15090997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy for hemophilia A.
    Connelly S; Kaleko M
    Thromb Haemost; 1997 Jul; 78(1):31-6. PubMed ID: 9198123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
    Reipert BM; van Helden PM; Schwarz HP; Hausl C
    Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates].
    Tavares A; Galvão M
    Acta Med Port; 1992 Dec; 5(11):587-90. PubMed ID: 1293952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and future approaches to inhibitor management and aversion.
    Hay C; Recht M; Carcao M; Reipert B
    Semin Thromb Hemost; 2006 Jun; 32 Suppl 2():15-21. PubMed ID: 16804831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
    J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
    Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
    Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
    Mannucci PM
    Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained expansion and transgene expression of coagulation factor VIII-transduced cord blood-derived endothelial progenitor cells.
    Herder C; Tonn T; Oostendorp R; Becker S; Keller U; Peschel C; Grez M; Seifried E
    Arterioscler Thromb Vasc Biol; 2003 Dec; 23(12):2266-72. PubMed ID: 14551158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
    Gouw SC; van den Berg HM
    Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.